Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
MLX 345 sought your views on the MHRA proposal for implementing a revised risk-based inspection programme for Good Practice inspections of manufacturers and/or importers and wholesale distributors of medicines for human use (GMP/GDP), manufacturers and/or importers of investigational medicinal products and contract research organisations (GMP and GCP), pharmacovigilance practices (GPvP) and good laboratory practices (GLP), known collectively as Good Practices (GxPs).
The deadline for comment was 15 January 2008.
The outcome of this consultation is available below as a download document.
Download documents:
-
Public consultation (MLX 345): MHRA consultation on a risk-based inspection programme for good practice inspections - Outcome (124Kb)
-
Public consultation (MLX 345): MHRA consultation on a risk-based inspection programme for good practice inspections (350Kb)
-
Public consultation (MLX 345): MHRA consultation on a risk-based inspection programme for good practice inspections - Consultation questions (31Kb)
